| DIRECT COMPETITOR COMPARISON | |
| TTHI | LXRX | STEM | Pvt1 | Industry | | Market Cap: | 80.80M | 326.81M | 157.40M | N/A | 109.35M | | Employees: | 28 | 347 | 55 | 981 | 68 | | Qtrly Rev Growth (yoy): | N/A | -71.60% | 1,945.10% | N/A | 19.10% | | Revenue (ttm): | 2.71M | 15.64M | 747.39K | 2.10M1 | 13.84M | | Gross Margin (ttm): | 100.00% | N/A | 73.11% | N/A | 65.67% | | EBITDA (ttm): | -19.81M | -82.37M | -25.17M | N/A | -11.53M | | Oper Margins (ttm): | -837.25% | -569.11% | -3,569.49% | N/A | -149.46% | | Net Income (ttm): | -22.08M | -76.19M | -31.88M | -39.50M1 | N/A | | EPS (ttm): | -0.954 | -0.556 | -0.321 | N/A | -0.31 | | P/E (ttm): | N/A | N/A | N/A | N/A | 20.53 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.35 | | P/S (ttm): | 31.35 | 20.90 | 213.77 | N/A | 9.90 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 55.5275 | -2.22% | 56.20B | 12.11 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 52.995 | -0.81% | 15.33B | 17.74 | | Genzyme Corp. | GENZ | 49.30 | 0.67% | 13.08B | 28.11 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 44.94 | 0.40% | 40.44B | 17.38 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 51.60 | -1.56% | 9.20B | 1053.06 | | Teva Pharmaceutical Industries Limited | TEVA | 57.4599 | 0.45% | 50.62B | 52.57 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.70 | -0.80% | 4.21B | 20.46 | | King Pharmaceuticals Inc. | KG | 12.76 | 0.63% | 3.17B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.235 | -0.57% | 5.57B | 111.87 | | Pfizer Inc. | PFE | 18.575 | -0.13% | 149.89B | 15.43 | | Johnson & Johnson | JNJ | 63.8566 | -0.92% | 176.19B | 13.95 | | GlaxoSmithKline plc | GSK | 41.311 | -0.07% | 104.72B | 13.50 | | Sanofi-Aventis | SNY | 40.012 | -0.67% | 104.48B | N/A | | Novartis AG | NVS | 52.07 | -0.57% | 118.26B | 15.59 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.01 | -1.40% | N/A | N/A | | AstraZeneca plc | AZN | 46.44 | 0.78% | 67.34B | 9.33 | | Abbott Laboratories | ABT | 54.36 | 0.07% | 84.08B | 14.73 | | Bristol-Myers Squibb Co. | BMY | 25.2779 | 0.23% | 50.08B | 13.08 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | LXRX | | UPDATE - Incyte sells autoimmune therapies to Lilly
Mon, Dec 21 -
at Reuters | | • | STEM | | StemCells, Inc. Strengthens Patent Position in Embryonic and Induced Pluripotent Stem Cell Technology Platforms
Tue, Dec 15 -
Business Wire | | • | STEM | | Interim Data Lifts Geron, Stem Cell Rivals Mixed
Tue, Dec 8 -
Indie Research | | • | STEM | | StemCells, Inc. Welcomes Approval of First Embryonic Stem Cell Lines Under New NIH Guidelines
Thu, Dec 3 -
Business Wire | | • | STEM | | Biotech cos. rise as gov't OKs new stem cell lines
Wed, Dec 2 -
AP | | • | STEM | | Geron, StemCells: Late Day Volume Plays
Wed, Dec 2 -
at TheStreet.com | | • | LXRX | | 5 Top Stocks at Half Price
Tue, Dec 1 -
at Motley Fool | | • | LXRX | | Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Mon, Nov 23 -
PR Newswire | | • | LXRX | | [$$] Small Stocks Gain on Week
Fri, Nov 13 -
at The Wall Street Journal Online | | • | LXRX | | Lexicon says IBS drug met mid-stage study goal
Fri, Nov 13 -
AP | | | All Headlines for these symbols... |
|
|
|
0.01% Nasdaq 
0.33%
Competitors
